NeoGenomics has successfully completed an upsized private offering of convertible senior notes, raising a total of $316.25 million in aggregate principal. The offering included an initial $275.0 million plus an additional $41.25 million from the full exercise of the initial purchasers' option. Concurrently, the company repurchased a portion of its existing convertible notes and shares of its common stock.
Key Details
- Offering Details: The company issued $316.25 million of 0.75% Convertible Senior Notes, which will mature on July 1, 2032. Interest is payable semi-annually.
- Conversion Terms: The notes have an initial conversion price of approximately $14.16 per share, representing a 35% premium over the common stock's last reported sale price of $10.49 on June 16, 2026.
- Concurrent Transactions: The company used proceeds to repurchase approximately $276.0 million of its existing 0.25% convertible notes due 2028 and up to $25.0 million of its common stock at $10.49 per share.
- Dilution Mitigation: NeoGenomics entered into capped call transactions for approximately $28.7 million. These transactions are designed to reduce potential stock dilution upon conversion of the new notes, with a cap price initially set at $20.98 per share.